Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the signaling pathways and changes in gene
expression in melanocytes of subjects with a history of non-melanoma skin cancer who are
exposed to oral vitamin D. If vitamin D is found to inhibit a signaling pathway involved in
the development of melanoma such as BRAF, a protein involved in cell proliferation, then oral
vitamin D could be explored further as a chemoprevention for melanoma skin cancer.
Phase:
N/A
Details
Lead Sponsor:
Stanford University
Collaborators:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institutes of Health (NIH)
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins